FDA Says MGI Pharma Brain Tumor Ad Misleading
Posted on: Thursday, 1 February 2007, 09:01 CST
The FDA has judged that an advert made by MGI Pharma to promote its brain cancer product Gliadel Wafer is misleading, according to a letter released by the health authority.
Gliadel Wafer contains the cancer chemotherapeutic drug carmustine and is implanted directly into the tumor as an adjunct to surgery and radiation.
The FDA said that the two-page promotional piece is misleading because it fails to disclose the full indication and presents unsubstantiated claims regarding the product.
The FDA said that the advert states "take the path to avoid treatment delays," and "Gliadel works at day one," suggesting that early use of Gliadel Wafers provides clinical benefit during the 14 days from implantation to the start of radiation therapy, and represents the basis for effectiveness. The US regulator said that it was not aware of any evidence that the efficacy of Gliadel Wafer results from the ability to use the product at the time of surgery.
MGI Pharma was also criticised for failing to disclose that the product was approved for use in addition to surgery and radiation.
The agency requested that MGI Pharma immediately stop using the ad or any others that are similar. It also requested a written response from the company by February 9, 2007.
Source: Datamonitor
Related Articles
- MGI PHARMA and HELSINN Announce sNDA for Aloxi Capsules Accepted for Review By U.S. FDA
- FDA to Review MGI Pharma's Aquavan
- MGI PHARMA Announces Aquavan NDA Accepted for Review By U.S. FDA
- MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted for Review By U.S. FDA
- FDA Requests Additional Trial of Saforis, Says MGI Pharma
- MGI PHARMA Summarizes Clinical Data Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
- MGI PHARMA Announces Submission of Saforis(TM) NDA to U.S. FDA
- MGI PHARMA And SuperGen Provide Regulatory Status Updates For Dacogen(TM) (Decitabine) Injection For MDS; Approvable Letter Response Submitted to FDA; Confirms Phase 3 Results; European Regulatory Strategy Revised
- MGI PHARMA Completes Acquisition of Guilford Pharmaceuticals
 |
 |
User Comments (0)
RSS Feeds